ClinicalTrials.gg
CompletedNCT04763759Updated Nov 21, 2024

Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections

A Phase 1 interventional study of TRL1068, a human monoclonal antibody in Prosthetic Joint Infection, sponsored by Trellis Bioscience LLC. Completed at 9 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Trellis Bioscience LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making these pathogens substantially more susceptible to established antibiotic treatment regimens. This initial study is designed to assess overall safety and pharmacokinetics (PK) of TRL1068. The overall goal of the development program is to demonstrate that TRL1068 can facilitate effectiveness of a single stage joint replacement or preservation of the original infected prosthetic joint in a substantial proportion of patients with PJI.

Read the detailed description

Approximately 75% of all clinically significant human infections are estimated to be biofilm-related. Prosthetic joint infections are a classical example of difficult to eradicate infections associated with biofilm. Most Prosthetic Joint Infection (PJI) cases are caused by staphylococcal species (\~70%) with an increasing number being antibiotic-resistant (MRSA). In the US, two-stage revision is the standard of care for replacement of an infected prosthetic joint, and is associated with substantial costs and prolonged immobility. TRL1068 is a fully human antibody that has been shown in pre-clinical studies to disrupt biofilm. TRL1068 targets a highly conserved epitope on the DNABII family of bacterial DNA binding proteins that includes histone-like (HU) and integration host factor (IHF) proteins of clinically relevant Gram-positive and Gram-negative bacteria. The DNABII epitope bound by TRL1068 has no homologs in the human proteome.

02

Conditions studied

  • Prosthetic Joint Infection

Keywords

  • biofilm
  • antibiotic-resistant infections
03

In context

Lead sponsor

Trellis Bioscience LLC is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PJI of the knee or hip
  • Identified pathogen(s) must be susceptible to antibiotic regimen
  • Planned/scheduled for primary two-stage exchange arthroplasty
  • \< 40 kg/m²
  • Willing and able to provide written
  • Willing to perform and comply with all study procedures including attending clinic visits as scheduled.
  • Men and women of child bearing potential () must be willing to practice a highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Evidence of active infection other than bacterial PJI of the knee or hip
  • Inability to receive or intolerant to pathogen-appropriate systemic or oral antibiotic therapy
  • (COPD)
  • score > 6
  • Congestive heart failure
  • individuals, including those receiving immunosuppressive doses of
  • Active , or history of malignancy or chemotherapy within the past 2 years
  • Active or history of disease
  • Uncontrolled diabetes, defined as > 7.4%
  • abnormality on (ECG) that would preclude subject from undergoing two-stage exchange arthroplasty
  • Clinically significant serum chemistry or hematology abnormalities
  • Any acute illness within 14 days of Day 1 that could confound the evaluation of safety evaluation
  • Known or suspected intolerance or to any biologic medication
  • Received a therapeutic antibody or biologic within the 6 months prior to Screening
  • Positive serum test for pregnancy, pregnant, or nursing women
  • Positive reverse transcription polymerase chain reaction (RT -PCR) or alternative (antigen) test for acute respiratory syndrome coronavirus 2
  • History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the subject's ability to comply with the study requirements
  • Any other comorbidity or condition that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Dose Level 1- 6mg/kg

    Randomized 3:1 (TRL1068:placebo) via IV infusion

    Drug: TRL1068, a human monoclonal antibody

  • Experimental
    Dose Level 2- 15mg/kg

    Randomized 5:2 (TRL1068:placebo) via IV infusion

    Drug: TRL1068, a human monoclonal antibody

  • Experimental
    Dose Level 3- 30 mg/kg

    Randomized 5:2 (TRL1068:placebo) via IV infusion

    Drug: TRL1068, a human monoclonal antibody

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Abnormal Physical Examination Findings

    clinically significant abnormal physical exam findings will be reviewed

    Time frame: 16 weeks

  2. Incidence of Abnormal Serum Chemistries and Hematology

    clinically significant abnormal laboratory results will be reviewed

    Time frame: 16 weeks

  3. Incidence of Abnormal Vital Signs (Temperature)

    clinically significant abnormal temperatures will be reviewed

    Time frame: 16 weeks

  4. Incidence of Abnormal Vital Signs (Blood Pressure)

    clinically significant abnormal blood pressures will be reviewed

    Time frame: 16 weeks

  5. Incidence of Abnormal Vital Signs (Heart Rate)

    clinically significant abnormal heart rates will be reviewed

    Time frame: 16 weeks

  6. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    mortality and any other reported AEs and SAEs will be reviewed

    Time frame: 24 weeks

Secondary outcomes

  1. Characterize the pharmacokinetics (PK) of a single IV infusion of TRL1068

    Serum and synovial concentrations of TRL1068 will be determined by ELISA

    Time frame: 16 weeks

  2. Measure TRL1068 levels in synovial fluid on Day 8 and compare with plasma PK

    Serum and synovial concentrations of TRL1068 will be determined by ELISA

    Time frame: 1 week

  3. Assess the pharmacodynamics (PD) of TRL1068 (Colony Forming Units (CFUs) prosthesis)

    Number of CFUs from sonicated prosthetic device

    Time frame: 1 week

  4. Assess the pharmacodynamics (PD) of TRL1068 (CFUs spacer)

    Number of CFUs from sonicated orthopedic spacer

    Time frame: 12 weeks

  5. Assess the pharmacodynamics (PD) of TRL1068 (CRP)

    Inflammatory biomarker CRP

    Time frame: 16 weeks

  6. Assess the pharmacodynamics (PD) of TRL1068 (ESR)

    Inflammatory biomarker ESR

    Time frame: 16 weeks

  7. Assess the pharmacodynamics (PD) of TRL1068 (IL-6)

    Inflammatory biomarker IL-6

    Time frame: 16 weeks

  8. Assess the pharmacodynamics (PD) of TRL1068 (IL-10)

    Inflammatory biomarker IL-10

    Time frame: 16 weeks

  9. Assess the pharmacodynamics (PD) of TRL1068 (reinfection)

    Assessment for reinfection including need for further surgical interventions and overall outcome

    Time frame: 24 weeks

  10. Assess the immunogenicity of TRL1068 as measured by anti-drug antibodies (ADAs)

    Anti-drug antibodies (ADA), i.e. anti-TRL1068 antibodies in serum will determined by electrochemiluminescence assay.

    Time frame: 16 weeks

Other outcomes

  1. Exploratory outcome measure to determine CFUs

    The number of subjects with Colony Forming Units (CFUs) per mL ≥ 1 from sonicated prosthetic devices from placebo and TRL1068 treated groups will be compared.

    Time frame: 12 weeks

  2. Exploratory outcome measure to determine inflammation (CRP)

    The mean levels of C reactive protein (CRP) from placebo and TRL1068 treated groups will be compared.

    Time frame: 16 weeks

  3. Exploratory outcome measure to determine inflammation (ESR)

    The mean levels of erythrocyte sedimentation rate (ESR) from placebo and TRL1068 treated groups will be compared.

    Time frame: 16 weeks

  4. Exploratory outcome measure to determine inflammation (IL-6)

    The mean levels of Interleukin-6 (IL-6) from placebo and TRL1068 treated groups will be compared.

    Time frame: 16 weeks

  5. Exploratory outcome measure to determine inflammation (IL-10)

    The mean levels of Interleukin-10 (IL-10) from placebo and TRL1068 treated groups will be compared.

    Time frame: 16 weeks

  6. Exploratory outcome measure to determine infection in synovial fluid

    The number of subjects with CFUs/mL ≥ 1 from the synovial fluid from placebo and TRL1068 treated groups will be compared.

    Time frame: 1 week

  7. Exploratory outcome measure inflammation in the synovial fluid

    The mean synovial fluid total leukocyte cell counts of the consolidated placebo and TRL1068 treated groups will be compared.

    Time frame: 1 week

  8. Exploratory outcome measure to assess quality of life

    Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF) Short Form 6b from placebo and TRL1068 treated groups will be compared. This questionnaire has a score range from 6-30, with higher scores indicating higher functioning than lower scores.

    Time frame: 24 weeks

07

Study locations

9 sites
  • University of Alabama
    Birmingham, Alabama 35205, United States
  • USC
    Los Angeles, California 90033, United States
  • UCLA
    Santa Monica, California 90404, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • Gulfcoast Research Institute
    Sarasota, Florida 34232, United States
  • Phoenix Clinical Research
    Tamarac, Florida 33321, United States
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
08

References and documents

Publications

  • Conway J, Delanois RE, Mont MA, Stavrakis A, McPherson E, Stolarski E, Incavo S, Oakes D, Salvagno R, Adams JS, Kisch-Hancock A, Tenorio E, Leighton A, Ryser S, Kauvar LM, Bernthal NM. Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0065524. doi: 10.1128/aac.00655-24. Epub 2024 Jul 16. PubMed 39012102 ↗
  • Estelles A, Woischnig AK, Liu K, Stephenson R, Lomongsod E, Nguyen D, Zhang J, Heidecker M, Yang Y, Simon RJ, Tenorio E, Ellsworth S, Leighton A, Ryser S, Gremmelmaier NK, Kauvar LM. A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2292-301. doi: 10.1128/AAC.02588-15. Print 2016 Apr. PubMed 26833157 ↗
  • Xiong YQ, Estelles A, Li L, Abdelhady W, Gonzales R, Bayer AS, Tenorio E, Leighton A, Ryser S, Kauvar LM. A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00904-17. doi: 10.1128/AAC.00904-17. Print 2017 Oct. PubMed 28717038 ↗

Individual participant data

Plan to share: No — The study results have been published.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Mar 2024, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2021
First posted
Feb 21, 2021
StartActual
Feb 8, 2021
Primary completionActual
Mar 13, 2024
CompletionActual
Mar 13, 2024
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04763759
Lead sponsor
Trellis Bioscience LLC
Collaborators
University of California, Los Angeles, Biomedical Advanced Research and Development Authority, Wellcome Trust, Sinai Hospital of Baltimore, Gulfcoast Research Institute, Phoenix Clinical Research, University of Florida, University of Alabama at Birmingham, The Methodist Hospital Research Institute, University of Virginia, University of Southern California
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Feb 8, 2021
Primary completion
Mar 13, 2024
Completion
Mar 13, 2024
Last update
Nov 21, 2024

Study contacts

Nicholas Bernthal, MD
principal investigator · University of California, Los Angeles
Janet Conway, MD
principal investigator · Sinai Hospital of Baltimore
Edward Stolarski, MD
principal investigator · Gulfcoast Research Institute
Richard Berkowitz, MD
principal investigator · Phoenix Clinical Research
Luis Pulido, MD
principal investigator · University of Florida
Sameer Naranje, MD
principal investigator · University of Alabama at Birmingham
Stephen Incavo, MD
principal investigator · The Methodist Hospital Research Institute
Ian Duensing, MD
principal investigator · UVA
Daniel Oakes, MD
principal investigator · University of Southern California

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRL1068

Start the discussion